Research programme: antisense oligonucleotide therapeutics - RogCon U.R
Alternative Names: RCUR 313; RCUR SMPLatest Information Update: 28 Jan 2023
At a glance
- Originator RogCon U.R
- Developer Florey Institute of Neuroscience and Mental Health; Ionis Pharmaceuticals; RogCon U.R
- Class Antiepileptic drugs; Antisense oligonucleotides; Behavioural disorder therapies
- Mechanism of Action NAV1.2 voltage-gated sodium channel expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autistic disorder; Epilepsy
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Autistic-disorder in USA
- 28 Jan 2023 No recent reports of development identified for preclinical development in Epilepsy in USA
- 01 Dec 2018 Preclinical trials in Autistic disorder in USA (unspecified route) prior to December 2018 (RogCon U.R website, December 2018)